-
公开(公告)号：EP3774905A1
公开(公告)日：2021-02-17
申请号：EP19718651.3
申请日：2019-04-12
申请人： argenx BVBA , VIB VZW , Universiteit Gent
-
公开(公告)号：EP3728328A1
公开(公告)日：2020-10-28
申请号：EP18830279.8
申请日：2018-12-21
申请人： Argenx BVBA
IPC分类号： C07K16/46
-
公开(公告)号：EP3625249A1
公开(公告)日：2020-03-25
申请号：EP18725795.1
申请日：2018-05-10
申请人： Argenx BVBA
IPC分类号： C07K16/00
-
公开(公告)号：EP3087095B1
公开(公告)日：2019-08-07
申请号：EP14827372.5
申请日：2014-12-23
-
5.发明公开METHODS OF REDUCING SERUM LEVELS OF FC-CONTAINING AGENTS USING FCRN ANTAGONSITS 审中-公开使用FCRN抗体降低含FC剂的血清水平的方法
公开(公告)号：EP3268391A1
公开(公告)日：2018-01-17
申请号：EP16719896.9
申请日：2016-03-08
申请人： argenx BVBA
发明人： ONGENAE, Nicolas, G.h. , DREIER, Torsten , ULRICHTS, Peter , DE HAARD, Johannes , BLANCHETOT, Christophe
CPC分类号： C07K16/283 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/00 , C07K16/2875 , C07K16/2887 , C07K16/40 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/732 , C07K2317/76
摘要： Provided are novel methods of reducing the serum levels of Fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn-antagonist that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. The disclosed methods are particularly useful for treating antibody-mediated disorders (e.g. autoimmune diseases).
-
6.发明公开
公开(公告)号：EP3972643A1
公开(公告)日：2022-03-30
申请号：EP20729653.4
申请日：2020-05-21
申请人： Argenx BVBA
发明人： BLANCHETOT, Christophe , BUDDING, Kevin , HACK, Erik , SILENCE, Karen , VAN DE WALLE, Inge , VAN DER POL, Ludo , BOROSS, Peter
IPC分类号： A61K39/395 , A61P25/02
-
公开(公告)号：EP4006051A1
公开(公告)日：2022-06-01
申请号：EP21189336.7
申请日：2016-03-08
申请人： Argenx BVBA
发明人： ONGENAE, Nicolas, G.h , DREIER, Torsten , ULRICHTS, Peter , DE HAARD, Johannes , BLANCHETOT, Christophe
IPC分类号： C07K16/00 , A61K38/17 , A61K45/06 , C07K16/28 , C07K16/40 , C07K14/47 , A61K39/00 , A61P21/04 , A61P25/00 , A61P25/08 , A61P43/00 , A61P7/00 , A61P37/06
摘要： Provided are novel methods of reducing the serum levels of Fc-containing agents (e.g., antibodies and immunoadhesins) in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn-antagonist that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. The disclosed methods are particularly useful for treating antibody-mediated disorders (e.g. autoimmune diseases).
-
公开(公告)号：EP3893924A1
公开(公告)日：2021-10-20
申请号：EP19832737.1
申请日：2019-12-13
申请人： Argenx BVBA
IPC分类号： A61K39/00 , A61K39/395 , A61P35/02 , C07K16/28 , C07K16/30 , A61P37/06 , C07K14/435 , C07K16/18
-
公开(公告)号：EP3626738A1
公开(公告)日：2020-03-25
申请号：EP19189186.0
申请日：2014-12-23
发明人： ULRICHTS, Peter , BLANCHETOT, Christophe , DREIER, Torsten , DE HAARD, Johannes , WARD OBER, E., Sally , ONGENAE, Nicolas G.H.
摘要： Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.009 秒)
